3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
5
Phase 2
3
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
8
Neoplasms
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Leukemia, Myeloid, Acute
4
Hematologic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Pulmonary Disease, Chronic Obstructive
2
Neoplasm Metastasis
2
Lymphoma, Follicular
2
Leukemia
2
Colonic Neoplasms
2
COVID-19
2
Xerostomia
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Teratoma
1
Stroke
1
Stomatitis
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Interventions
Paclitaxel
23
Carboplatin
22
Capecitabine
18
Gemcitabine
16
130-nm albumin-bound paclitaxel
16
pembrolizumab
14
Cyclophosphamide
12
atezolizumab
9
Epirubicin
9
sacituzumab govitecan
8
Albumin-Bound Paclitaxel
8
eribulin
6
Vinorelbine
6
Drug Therapy
6
Doxorubicin
6
camrelizumab
4
Docetaxel
4
Cisplatin
4
Injections
3
pegfilgrastim
2
olaparib
2
famitinib
2
Filgrastim
2
Everolimus
2
veliparib
1
trilaciclib
1
toripalimab
1
taxane
1
niraparib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Triple Negative Breast Neoplasms
×
Standard of Care
×
Clear all
NCT07486687
2026-03-20
PLANET
The Netherlands Cancer Institute
Phase 3
Not yet recruiting
1,000 enrolled